«Every diagnosis is actionable.» – Reimbursement of paediatric exome sequencing
A qualitative expert interview study from Germany and Switzerland
In our qualitative study on ethical considerations in paediatric genome-wide sequencing, the frequently lacking reimbursement by health insurers and related legal aspects were described as a significant problem. Insufficient social insurance regulations and an inconsistent or overly narrow interpretation of existing regulations in Switzerland appeared as decisive reasons. This article presents the results of this aspect of the study, analyses the legal framework, and examines underlying ethical concepts.
Table of contents
- 1. Background
- 2. Methods
- 3. Results
- 3.1. The problem of strict and inconsistent reimbursement of exome sequencing by health insurers
- 3.2. The consequences of strict and inconsistent reimbursement of exome sequencing by health insurers
- 3.2.1. Inequality
- 3.2.2. Delays in diagnostic process
- 3.2.3. Regulations out of step with advances in diagnostic possibilities
- 3.3. The importance of taking a broader interpretation of therapeutic and social consequences
- 4. Discussion
- 5. Conclusion
Loggen Sie sich bitte ein, um den ganzen Text zu lesen.
Es gibt noch keine Kommentare
Votre commentaire sur cet article
Les abonné-e-s à cette revue peuvent prendre part à la discussion. Veuillez vous connecter pour poster des commentaires.
Aucun commentaire